Intellia, Morgan Stanley

Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal Weight’ from ‘Overweight,’ slashing its price target from $56 to $11. The downgrade and what the brokerage says is a broader lack of catalysts for the year dented retail sentiment,
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan Stanley
Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal weight rating in a report published on Monday morning, MarketBeat.com reports.
Intellia downgraded at Morgan Stanley on lowered expectations for rare disease asset
Morgan Stanley has downgraded Intellia Therapeutics (NASDAQ:NTLA) to equal weight from overweight citing "a more measured launch" of its transthyretin amyloidosis (ATTR) candidate nexiguran ziclumeran.
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now
Morgan Stanley cuts Intellia stock rating amid gene editing concerns
Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also significantly reduced its price target to $11.
Intellia Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - NTLA
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.
Yahoo Finance13d
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization. Intellia is a clinical-stage gene editing company ...
Bronstein, Gewirtz & Grossman, LLC Encourages Intellia Therapeutics, Inc. (NTLA) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...